Skip to main content
lexblog.com/lib/6GJ2CW7Hviewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "OIG Report on Topical Compounded Drug Prescribing, Marketing and Billing Practices Signals Heightened Administrative and Enforcement Scrutiny",
    "url": "https://www.lexblog.com/2018/11/02/drug-pricing-medicare-part-d-2/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-6GJ2CW7H",
        "url": "https://www.lexblog.com/lib/6GJ2CW7H/"
    },
    "datePublished": "2018-11-02T14:39:01-04:00",
    "dateModified": "2021-02-10T14:44:42-05:00",
    "author": {
        "@type": "Person",
        "name": "Kathleen Stratton"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Sheppard, Mullin, Richter & Hampton LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Organizational Integrity Group Blog",
    "about": "Other",
    "sourceUrl": "https://www.fcadefenselawblog.com/?p=1538",
    "sourceStability": "may-move"
}